Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
📍 The outcome
Scribe Therapeutics, a gene-editing company focused on cardiovascular diseases, filed for a $75 million IPO on the Nasdaq. The company's stockholders include Eli Lilly.
The story quieted without a definitive conclusion in the coverage.
Epilogue added 88d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
- Velocity & Diffusion: Coverage escalated across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Scribe Therapeutics, a biotech company focused on cardiovascular diseases, has filed for a $75 million IPO. The company, based in Alameda, uses gene-editing technology to fight cholesterol.
Coverage from Renaissance Capital, The Business Journals, Investing.com, Moomoo, and Endpoints News highlights Scribe Therapeutics' stockholder list, which includes Eli Lilly. The IPO will be listed on Nasdaq, but coverage does not yet specify when it will take place or how the public will respond.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 91d ago.
Who reported it (5)
-
-
-
-
-
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs Endpoints News · 92d ago broke it first
Quick answers
What is Scribe Therapeutics' focus?
Cardiovascular diseases
How much is Scribe Therapeutics seeking in its IPO?
$75 million
Who is a notable stockholder in Scribe Therapeutics?
Eli Lilly
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Topics
Related trends
Sam Altman: OpenAI won't go public this year as IPO now would come at an 'ill-advised moment'
OpenAI will not pursue an initial public offering in 2026, according to statements from Sam Altman.
Nasdaq Invests in Kraken Parent Payward at $21 Billion Valuation
Nasdaq is investing $100 million in Kraken parent Payward at a $21 billion valuation to expand tokenized stocks.
Exclusive | Anthropic Researcher Quits Over ‘Out-of-Control’ AI Fears
An Anthropic core researcher has abruptly resigned, warning that labs are gambling with humanity in the race toward superintelligence.
Stock Market Today: Dow tumbles 1%, S&P 500 and Nasdaq drop as Brent crude edges toward $100 a barrel and pharma stocks stumble
Wall Street extends losses as major indexes slide, pharmaceutical shares drop, and oil surges amid geopolitical tensions.
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
JBS Proposes to Acquire Remaining Stake in Pilgrim’s Pride
JBS has proposed acquiring the remaining publicly traded shares of Pilgrim's Pride, which could result in a Nasdaq delisting.